A BMC Cancer study fuses a blood-based inflammation index with clinical variables including age, smoking history, and AJCC stage to build a lung cancer survival model. The model held up under internal and external validation protocols, though the study notes potential issues with absolute survival calibration. The key advance is integrating routine blood markers into prognostic modeling rather than relying on imaging alone. For drug developers, the approach supports more consistent patient stratification in trials where survival endpoints and treatment effects depend on baseline risk quality.